Viral Myocarditis Causes Chest Pain and Heart Failure in Young Adults. Cardiac MRI Is the Diagnostic Standard.

What It Is

Myocarditis is inflammatory disease of the myocardium (heart muscle) diagnosed by histological, immunological, or immunohistochemical criteria. In clinical practice, it is typically diagnosed by cardiac MRI or, less commonly, endomyocardial biopsy.

It exists on a spectrum from subclinical (detected only on cardiac MRI obtained for another reason) to mild-to-moderate with preserved left ventricular function and excellent prognosis, to fulminant myocarditis with acute severe ventricular dysfunction, cardiogenic shock, and a mortality risk that requires mechanical circulatory support.

Myocarditis is the third most common cause of sudden cardiac death in young adults, after hypertrophic cardiomyopathy and anomalous coronary arteries 5 / Solid . It is estimated to cause 10 to 20 percent of sudden cardiac death in athletes under 35 years old.

Classification

Acute myocarditis: Active inflammation with onset within the preceding four weeks.

Chronic myocarditis: Ongoing inflammation for more than three months.

Fulminant myocarditis: Acute, severe myocarditis with rapid onset of hemodynamic compromise requiring inotropic support or mechanical circulatory support (intra-aortic balloon pump, Impella, ECMO). Paradoxically, fulminant myocarditis has a better long-term prognosis than non-fulminant acute myocarditis if the patient survives the acute phase: once the acute insult resolves, the myocardium recovers more completely than in the slower smoldering presentation.

Giant cell myocarditis: A rare, aggressive form with characteristic multinucleated giant cells on biopsy. Associated with autoimmune conditions, thymoma, and inflammatory bowel disease. Rapidly progressive, with high mortality without immunosuppression and cardiac transplantation.

The Mechanism

Viral Myocarditis: The Three-Phase Model

The best-characterized mechanism is that of viral myocarditis, which accounts for the majority of cases in the developed world. The process unfolds in three phases:

Phase 1 (0 to 4 days): Direct viral injury. The cardiotropic virus (Coxsackievirus B3 is the prototype, but adenovirus, parvovirus B19, Epstein-Barr virus, cytomegalovirus, SARS-CoV-2, and influenza are all documented) enters cardiomyocytes via specific receptor binding. Coxsackievirus B binds the coxsackievirus-adenovirus receptor (CAR) on cardiomyocyte surfaces and is internalized. Direct cytopathic effect begins within hours. The virus replicates inside cardiomyocytes, causing cell death and inflammatory signaling.

Phase 2 (4 to 14 days): Immune-mediated injury. Natural killer cells, macrophages, and cytotoxic T cells infiltrate the myocardium to clear infected cells. This immune response is essential for viral clearance but collateral damage to surrounding uninfected myocardium is substantial. Pro-inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1, interleukin-6) depress myocardial contractility directly.

Phase 3 (14+ days): Recovery or chronic disease. In most patients (greater than 80 percent), inflammation resolves and ventricular function recovers over weeks to months. In a subset, viral persistence or ongoing autoimmune reactivity (molecular mimicry, in which the immune system continues attacking myocardial proteins that share epitopes with the cleared virus) sustains inflammation and leads to dilated cardiomyopathy.

COVID-19 Myocarditis

SARS-CoV-2 is now among the most common identified causes of viral myocarditis. The mechanism involves both direct ACE2 receptor-mediated viral entry into cardiomyocytes and immune-mediated injury from the cytokine storm of severe COVID-19. Cardiac MRI studies performed on COVID-19 survivors (including those with mild illness) have shown myocardial inflammation in 20 to 60 percent of patients in early studies, though methodological concerns and declining effect sizes in subsequent studies have tempered initial alarmism.

Vaccine-associated myocarditis (VAMC) following mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) is predominantly a condition of young males (16 to 29 years) within seven days of the second dose. The CDC VAERS data and active surveillance studies estimate a rate of 12 to 25 per 100,000 doses in young males, compared to a background rate of myocarditis in this group of approximately 1 to 10 per 100,000 per year. The clinical course of VAMC is almost uniformly mild and self-limited, with recovery of cardiac function in over 99 percent of cases 5 / Solid . The myocarditis risk from COVID-19 infection itself substantially exceeds the vaccine-associated risk in comparative analyses 5 / Solid .

Autoimmune Myocarditis

Autoimmune myocarditis, including giant cell myocarditis and eosinophilic myocarditis, results from direct immune attack on myocardial tissue without a viral trigger. Checkpoint inhibitor therapy (PD-1 and CTLA-4 inhibitors used in cancer treatment) has emerged as an important cause of fulminant immune myocarditis, with case fatality rates of 25 to 50 percent in registry series 5 / Solid . Any patient on checkpoint inhibitor therapy who develops new cardiac symptoms requires urgent evaluation including troponin, ECG, and echocardiography.

How We Diagnose

The Dallas Criteria and Their Limitations

The historical gold standard for myocarditis diagnosis was the Dallas criteria: histopathological demonstration of inflammatory infiltrates with adjacent myocyte necrosis on endomyocardial biopsy. Dallas criteria myocarditis was present in only 10 to 17 percent of biopsies from patients with clinically suspected myocarditis in early studies, because the focal and patchy distribution of inflammation means the biopsy needle often samples uninvolved tissue. The Dallas criteria have been largely supplanted by cardiac MRI and the Lake Louise Criteria in contemporary practice.

The Lake Louise Criteria: Cardiac MRI for Myocarditis

The Lake Louise Criteria (updated 2018) provide a standardized framework for cardiac MRI diagnosis of myocarditis, requiring:

1. T2-based criteria (edema): Regional or global myocardial T2 signal intensity ratio greater than 2.0, OR focal myocardial T2 elevation on T2 mapping.

2. T1-based criteria (tissue injury/fibrosis): Raised myocardial T1 values or extracellular volume (ECV) fraction on T1 mapping, AND/OR late gadolinium enhancement (LGE) in a non-ischemic pattern.

The presence of at least one T2-based and one T1-based criterion yields a diagnostic sensitivity of approximately 87 percent and specificity of approximately 96 percent for active myocarditis in the appropriate clinical context 5 / Solid .

The pattern of late gadolinium enhancement is critical: ischemic LGE starts in the subendocardium and extends outward (subendocardial to transmural). Myocarditis LGE is characteristically epicardial (in the outermost layer of the myocardium) or mid-myocardial. This pattern reflects the distribution of inflammation, which in viral myocarditis tends to spare the endocardium.

Biomarkers

Cardiac troponin I or T. Raised in approximately 50 to 80 percent of patients with acute myocarditis. The degree of elevation correlates with the extent of myocyte necrosis but not necessarily with the severity of ventricular dysfunction. Troponin elevation in a young patient with a viral prodrome, in the absence of regional wall motion abnormality or risk factors for coronary artery disease, should prompt cardiac MRI.

High-sensitivity CRP and ESR. Raised in most cases, reflecting systemic inflammation. Not diagnostic but support the diagnosis in context.

NT-proBNP. Raised proportionally to the degree of left ventricular dysfunction. Useful for monitoring recovery.

Endomyocardial Biopsy

Biopsy is reserved for:

• Clinically suspected giant cell myocarditis (rapidly progressive course, new high-degree AV block, ventricular arrhythmia refractory to management)
• Hemodynamically unstable patients requiring mechanical circulatory support where histology will guide immunosuppression
• Cardiac MRI findings that do not conclusively differentiate myocarditis from sarcoidosis

In most non-fulminant presentations, cardiac MRI is sufficient for diagnosis and biopsy is not required.

The Evidence

TIMIC Trial: Colchicine in Acute Myocarditis

The TIMIC trial (Treating Idiopathic recurrent pericarditis and Myocarditis with Interleukin-1 Colchicine) randomized 90 patients with idiopathic recurrent pericarditis or myocarditis to colchicine versus placebo for six months. In the myocarditis subgroup, colchicine significantly reduced symptom persistence and normalization of troponin at six months 4 / Promising 01354-6). The sample size in the myocarditis subgroup was small, but the result has moved practice toward offering colchicine as adjunct therapy in selected cases.

BAMI Trial: Beta-Blockers in Myocarditis

The BAMI trial examined whether beta-blockers improved outcomes in patients with reduced ejection fraction after acute myocarditis. The trial was underpowered and did not show a definitive benefit specifically from beta-blockers over standard heart failure management 3 / Early . Standard heart failure neurohormonal therapy (ACE inhibitor or ARB, beta-blocker, mineralocorticoid antagonist in appropriate patients) is used in myocarditis patients with reduced EF based on extrapolation from the heart failure evidence base, not from myocarditis-specific trials.

ESBY Steroids Trial: Immunosuppression in Myocarditis

The ESBY trial randomized patients with virus-negative (by biopsy PCR) lymphocytic myocarditis to conventional therapy versus prednisone plus azathioprine immunosuppression. Immunosuppression significantly improved ejection fraction at six months compared to conventional therapy alone (56 percent vs. 45 percent EF; p=0.007) 4 / Promising . This represents the strongest evidence for immunosuppression in a defined subset of myocarditis: the key distinction is virus-negative status. Immunosuppression in active viral myocarditis can worsen outcomes by impairing viral clearance.

Giant cell myocarditis has the strongest evidence for immunosuppression: combined immunosuppression (corticosteroids plus ciclosporin or azathioprine) has been associated with improved transplant-free survival in registry data and is a Class I recommendation in the 2013 ESC myocarditis guidelines 5 / Solid .

Checkpoint Inhibitor Myocarditis

For immune checkpoint inhibitor (ICI)-related myocarditis, high-dose corticosteroids (methylprednisolone 1 to 2 mg/kg/day) are the first-line treatment. For steroid-refractory cases, additional immunosuppression with mycophenolate mofetil, tacrolimus, or abatacept (a CTLA-4 agonist, which specifically counteracts the mechanism of CTLA-4 inhibitor toxicity) has been used with varying results 3 / Early . Checkpoint inhibitor myocarditis must be distinguished from other forms of myocarditis in the history, and the decision to permanently discontinue the checkpoint inhibitor versus rechallenge is complex and must involve the oncology team.

ULTIMA and Mechanical Circulatory Support

Fulminant myocarditis with cardiogenic shock carries a high short-term mortality without mechanical circulatory support. The Impella CP or Impella 5.0 (left ventricular assist devices) can unload the failing ventricle and maintain systemic perfusion while the myocarditis resolves. Veno-arterial ECMO provides biventricular support when both ventricles are failing. These are bridges to recovery (anticipating myocardial recovery as inflammation resolves), not permanent solutions. The prognosis for fulminant myocarditis is paradoxically better than for non-fulminant acute myocarditis: in case series from experienced centers, 70 to 80 percent of fulminant myocarditis patients who survive the acute phase recover normal or near-normal ventricular function 4 / Promising .

The Patient Experience

The Diagnostic Uncertainty

Myocarditis presents a particular diagnostic challenge because its symptoms (chest pain, dyspnea, palpitations, fatigue) overlap extensively with entities that carry different urgency levels: pericarditis (very common, generally self-limiting), pulmonary embolism (dangerous, requires anticoagulation), and myocardial infarction (dangerous, requires revascularization).

In a young patient with chest pain and troponin elevation, the first question the cardiologist must answer is: is there an obstructed coronary artery? If the ECG shows regional ST changes, if the echo shows a regional (not global) wall motion abnormality corresponding to a coronary territory, or if the patient has coronary risk factors, coronary angiography is performed before cardiac MRI. In a young patient with diffuse ST changes, a viral prodrome, and global hypokinesis on echo, cardiac MRI is the appropriate next step without angiography.

Patients experience the diagnostic workup as a period of frightening uncertainty. They understand they have a heart problem but do not yet understand the severity. The communication task during the diagnostic phase is to provide enough information to reduce catastrophic interpretation (“I am dying”) while maintaining appropriate seriousness about the diagnosis.

Activity Restriction

The most practically impactful restriction for young patients with myocarditis is physical activity. Competitive sports and high-intensity exercise are prohibited during the acute phase and for at least three to six months afterward, regardless of symptom resolution. The reason is that exercise increases heart rate, myocardial oxygen demand, and catecholamine exposure, all of which can trigger fatal arrhythmias in an inflamed, electrically unstable myocardium.

The data behind this restriction comes primarily from autopsy series showing myocarditis as a contributing cause in exercise-related sudden cardiac death in young athletes, and from animal models demonstrating dramatically increased mortality when mice with viral myocarditis exercise compared to those that rest. There is no randomized trial, and the duration of restriction is based on consensus expert opinion and the trajectory of biomarker and imaging normalization.

For a 19-year-old college athlete, this means being told he cannot play, train, or compete for months. This is a real loss that deserves to be named as such in the clinical conversation, not minimized.

Recovery and Prognosis

Most patients with acute non-fulminant myocarditis and mildly reduced EF recover ventricular function over three to six months. The return to normal EF is the rule, not the exception, in this group. Cardiac MRI at three to six months typically shows resolution of T2 edema, though late gadolinium enhancement (representing myocardial fibrosis from healed necrosis) may persist.

Persistent LGE on follow-up cardiac MRI is associated with higher long-term risk of ventricular arrhythmia and sudden cardiac death 4 / Promising . This finding influences the decision about implantable cardioverter-defibrillator (ICD) implantation in patients with persistent severe LV dysfunction and LGE at six or more months.

Decisions and Trade-Offs

Inpatient vs. Outpatient Management

Most patients with acute myocarditis and preserved or mildly reduced EF can be managed as inpatients for the diagnostic workup and initial observation period (typically 24 to 72 hours), then discharged with close outpatient follow-up. Indications for extended hospitalization or intensive care unit monitoring:

• EF below 40 percent
• Hemodynamic instability
• Sustained ventricular arrhythmia
• High-degree AV block
• Giant cell myocarditis or ICI-related myocarditis

The decision tree is relatively simple: hemodynamically stable patients with good EF can be observed in a step-down unit; hemodynamically unstable patients or those with rapidly declining EF require ICU management with access to mechanical circulatory support.

Immunosuppression: The Virus-Negative Requirement

The ESBY trial’s most important practical implication is that immunosuppression should not be initiated in myocarditis without excluding active viral infection. In practice, this means either performing endomyocardial biopsy with viral PCR testing on myocardial tissue, or in centers where biopsy is not available or the biopsy risk is high, treating conservatively with standard heart failure therapy and reserving immunosuppression for patients with severe or deteriorating disease and no identifiable viral etiology.

Giving immunosuppression to a patient with active viral myocarditis can impair the immune response necessary to clear the virus, prolonging the viral phase and potentially worsening myocardial injury. This is the central risk.

Arrhythmia Risk in Myocarditis

Ventricular arrhythmia is the mechanism of sudden cardiac death in myocarditis. The inflamed, ischemic myocardium creates heterogeneous areas of electrical conduction, where normal and abnormal tissue are adjacent. This heterogeneity creates the substrate for reentrant ventricular tachycardia (VT): electrical circuits that activate repetitively without needing an external trigger.

The arrhythmia risk in myocarditis is concentrated in two time windows. The first is the acute phase (first two to four weeks): the actively inflamed myocardium is the most electrically unstable, and fatal ventricular fibrillation can occur even in patients with apparently mild disease. This is the period when continuous cardiac monitoring in an inpatient setting is most important for patients with significantly reduced EF or documented arrhythmia on initial presentation.

The second risk window is long-term, after apparent recovery. Patients with persistent late gadolinium enhancement (LGE) on follow-up cardiac MRI, representing healed myocardial fibrosis, have a substrate for arrhythmia that persists even after inflammation has resolved. Multiple studies have demonstrated that LGE extent on follow-up MRI is an independent predictor of sustained VT and sudden cardiac death, with hazard ratios of 4 to 8 compared to patients without LGE 4 / Promising .

This long-term arrhythmia risk is the primary reason that complete clearance before return to competitive athletics requires more than normalization of EF. An athlete whose EF has recovered to 60 percent but who has extensive LGE on cardiac MRI may still harbor a substrate for exercise-induced fatal arrhythmia. The electrophysiology consultation for such athletes is not bureaucratic: it is clinically justified.

Endomyocardial Biopsy: Technique and Risk

When endomyocardial biopsy is indicated (suspected giant cell myocarditis, hemodynamic deterioration requiring mechanical circulatory support where histology will guide immunosuppression), the procedure involves introducing a bioptome (a long-handled biopsy forceps) through a jugular or femoral venous approach into the right ventricle under fluoroscopic or echocardiographic guidance. Multiple specimens (typically five to ten) are taken from the right ventricular septum to maximize sampling of inflamed tissue.

The major risks are cardiac perforation (approximately 0.5 percent), ventricular arrhythmia, and right bundle branch block from mechanical trauma. In experienced centers performing more than 20 biopsies per year, major complication rates are consistently below 1 percent. In lower-volume centers, rates are higher.

The diagnostic yield depends on the pathology: giant cell myocarditis has characteristic and easily recognizable histology (multinucleated giant cells, eosinophils, necrosis) and is diagnosed in a high proportion of biopsies in genuinely affected patients. Lymphocytic myocarditis (the common viral form) has much more patchy distribution; the Dallas criteria sensitivity is only 10 to 17 percent due to sampling error. The updated ESC criteria, which incorporate immunohistochemistry (CD3+ T cells greater than 7 per mm2, CD68+ macrophages greater than 14 per mm2), improve diagnostic sensitivity to approximately 50 to 65 percent for lymphocytic myocarditis.

Return to Exercise After Myocarditis

The question patients ask most urgently after myocarditis is: when can I exercise again? The American Heart Association and the European Society of Cardiology have published consensus statements recommending:

• No competitive sports or vigorous exercise for at least three to six months from diagnosis
• Return to exercise contingent on: normalization of EF, resolution of symptoms, normalization of troponin, and absence of significant arrhythmia on ambulatory monitoring
• Repeat cardiac MRI at three to six months before return to competitive athletics
• Electrophysiology consultation for athletes with persistent LGE or ventricular arrhythmia

The AHA 2022 return-to-play guidance specifically recommends a minimum of three to six months regardless of symptom duration and requires a structured evaluation before athletic clearance 5 / Solid .

Vaccine-Associated Myocarditis: The Risk Communication

The question of mRNA vaccine-associated myocarditis requires careful communication. The facts:

1. VAMC is real. It occurs in approximately 12 to 25 per 100,000 second doses in young males 16 to 29.
2. VAMC is almost always mild and self-limited. Recovery of cardiac function occurs in over 99 percent of cases.
3. The myocarditis risk from COVID-19 infection in unvaccinated individuals exceeds the vaccine-associated risk by a factor of 3 to 6 in comparative analyses.
4. The recommendation to vaccinate young males with mRNA vaccines is maintained by every major health authority.

Dismissing patient or family concerns about VAMC is counterproductive. Naming the signal, its magnitude, and the clinical context (mild, self-limited, smaller than infection risk) is both accurate and respectful of the real concerns that exist.

Clinical Synthesis

Myocarditis is the cardiology condition most likely to present in a young, otherwise healthy person who had no prior cardiovascular disease awareness. The program reaches this population not through the traditional cardiovascular risk factor screening pathway, but through education.

The practical contribution here is threefold.

First, symptom recognition. The 19-year-old in Champaign who went to campus health for chest pain and a flu-like illness two days earlier made the right decision. Many do not. The combination of viral prodrome, chest pain (pleuritic or atypical), and rapid heart rate in a young person is the clinical signal. Broad public familiarity with this pattern saves lives.

Second, return-to-sport clearance. Young athletes with myocarditis who resume competitive activity before formal clearance are at real risk for exercise-induced sudden cardiac death. A structured cardiovascular assessment for young athletes includes a structured post-myocarditis follow-up protocol: troponin normalization, echocardiographic recovery, cardiac MRI, and ambulatory arrhythmia monitoring before clearance is granted.

Third, post-myocarditis surveillance. Patients with persistent LGE on follow-up cardiac MRI at six months require continued surveillance for ventricular arrhythmia. A cardiologist-led preventive program includes coordination of this surveillance: ambulatory monitoring, annual echocardiography, and electrophysiology consultation when indicated.

For patients with giant cell myocarditis or ICI-related myocarditis: a structured post-care program facilitates connection to specialized programs at Northwestern Medicine in Chicago, the University of Chicago Medical Center, and Carle Foundation Hospital’s advanced heart failure program.

Mechanisms Extended: The Immunopathology of Myocarditis

Viral Entry and Immune Activation

Viral myocarditis begins with myocyte infection. Coxsackievirus B3, the best-studied myocarditis pathogen, enters cardiomyocytes through the coxsackievirus-adenovirus receptor (CAR), a cell-surface adhesion molecule expressed on cardiomyocyte intercalated discs. After receptor binding, the virus also requires the decay accelerating factor (DAF) for efficient cell entry.

Once inside the cardiomyocyte, the virus replicates and releases daughter virions that infect adjacent cells. Simultaneously, the host immune system detects the infection through pattern recognition receptors (Toll-like receptors TLR3 and TLR8, which recognize viral RNA), triggering type I interferon production and natural killer cell activation. This constitutes Phase 1 of myocarditis: direct viral cytopathic injury.

Phase 2, occurring over the first 1 to 4 weeks, involves T lymphocyte infiltration. CD8+ cytotoxic T cells recognize viral peptides presented on MHC class I molecules on infected cardiomyocytes and destroy them. CD4+ helper T cells coordinate the antibody response and amplify the inflammatory signal. The macrophage infiltrate produces TNF-alpha, IL-1 beta, and IL-6, which further depress myocardial contractility through calcium handling interference and nitric oxide-mediated negative inotropy.

Phase 3, the pathological phase that leads to dilated cardiomyopathy in a susceptible subset, involves immune dysregulation: the immune response fails to fully clear the viral antigen, molecular mimicry produces autoantibodies against cardiac proteins (myosin heavy chain, troponin, cardiac calcium channels), and the chronic inflammatory cycle drives progressive myocardial fibrosis. The cardiac beta-1 adrenergic receptor is a specific autoantibody target: anti-beta-1 receptor antibodies produce a functionally stimulating effect on cardiomyocytes that, paradoxically, leads to calcium overload and cell death 4 / Promising .

Giant Cell Myocarditis: The Most Aggressive Form

Giant cell myocarditis (GCM) is a rare but fulminant form characterized by multinucleated giant cells, extensive eosinophilic and lymphocytic infiltrates, and extensive myocardial necrosis on biopsy. It is not caused by a virus. The etiology appears to be autoimmune: GCM occurs more often in patients with concurrent autoimmune diseases (inflammatory bowel disease, myasthenia gravis, thyroiditis) and responds to immunosuppression.

GCM is the form of myocarditis most likely to cause rapid hemodynamic collapse and death without MCS or transplantation. Median survival from symptom onset to death or transplantation without treatment is 5.5 months 5 / Solid . High-dose immunosuppression (cyclosporine plus corticosteroids, sometimes azathioprine) combined with mechanical circulatory support as a bridge to either recovery or transplant is the treatment framework. GCM recurs in transplanted hearts in approximately 25 percent of cases, requiring ongoing immunosuppression post-transplant.

Eosinophilic myocarditis is another aggressive rare variant, occurring in the context of hypereosinophilic syndrome, parasitic infections (Toxocara, Trypanosoma), hypersensitivity reactions to medications (clozapine, sulfonamides, some antibiotics), and as a paraneoplastic phenomenon. It carries a better prognosis than GCM when the eosinophilic trigger is identified and removed.

COVID-19 Myocarditis and Vaccine-Associated Myocarditis

The SARS-CoV-2 pandemic introduced two new myocarditis contexts: myocarditis from COVID-19 infection itself and myocarditis associated with mRNA COVID-19 vaccines.

COVID-19-associated myocarditis appears to occur through a combination of direct viral myocardial infection (ACE2 receptors are expressed on cardiomyocytes), cytokine storm, and microthrombus formation in small coronary arteries. Cardiac MRI studies of patients recovered from moderate to severe COVID-19 showed myocardial inflammation markers in a significant proportion, though the clinical significance of many of these findings has been debated 4 / Promising .

mRNA vaccine-associated myocarditis emerged as a signal after the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) vaccines were widely administered. The incidence is highest in male adolescents and young adult males (16 to 30 years old) after the second dose. Rates in this demographic have been estimated at 12 to 22 per 100,000 second doses in some vaccine surveillance programs 5 / Solid . The clinical presentation is typically mild: chest pain with ECG changes and raised troponin, with preserved EF on echocardiography. Most cases resolve completely within days to weeks. Severe or fatal cases have been extremely rare.

The CDC’s Advisory Committee on Immunization Practices concluded that the benefits of mRNA vaccination strongly outweigh the myocarditis risk, particularly given the much higher rates of severe myocarditis from COVID-19 infection itself 5 / Solid . Cardiologists evaluating young males with possible vaccine-associated myocarditis should use cardiac MRI if troponin is raised, restrict competitive athletic activity until MRI shows resolution, and follow the same return-to-play criteria as for other myocarditis forms.

Advanced Diagnostics

Cardiac MRI Protocol for Myocarditis

Cardiac MRI has replaced endomyocardial biopsy as the first-line confirmatory test for myocarditis in most clinical scenarios. The Lake Louise Criteria, updated in 2018, define CMR-based myocarditis as: raised T2 signal (indicating edema) combined with raised T1 signal or extracellular volume (ECV) fraction (indicating inflammation), or both, in the appropriate clinical context 5 / Solid .

Late gadolinium enhancement (LGE) is present in approximately 75 to 90 percent of proven myocarditis cases. The distribution of LGE distinguishes myocarditis from ischemic injury: myocarditis characteristically produces mid-wall or subepicardial (outer layer) LGE, particularly in the inferolateral wall. Ischemic LGE is subendocardial (inner layer) or transmural, following coronary artery territory.

T1 and T2 mapping sequences, which quantify myocardial tissue relaxation times as objective numbers rather than visual signal estimation, improve the reproducibility and sensitivity of CMR for myocarditis. Native T1 above 1,050 ms and T2 above 55 ms (values that vary by CMR system and protocol) suggest active inflammation 4 / Promising . These quantitative methods are now available at most CMR-equipped centers including Carle Foundation Hospital.

Endomyocardial Biopsy: When and How

Endomyocardial biopsy remains the definitive diagnostic test for specific myocarditis subtypes where the diagnosis changes management: giant cell myocarditis (requires high-dose immunosuppression), cardiac sarcoidosis (requires steroid therapy and ICD evaluation), and eosinophilic myocarditis. For idiopathic or presumed viral myocarditis, biopsy adds confirmatory information but rarely changes management in most patients.

The biopsy is performed via a femoral or internal jugular venous approach, advancing a bioptome (a catheter with a cutting jaw at its tip) to the right ventricular septum under fluoroscopic or echocardiographic guidance. Samples of approximately 1 to 2 mm are obtained from the mid-right ventricular septum. Six to eight samples are recommended to improve sampling yield, because myocarditis is patchy and a small biopsy from an unaffected area will be falsely negative.

The Dallas Criteria (1986) defined histological myocarditis as lymphocytic infiltration plus myocyte necrosis. These criteria have been criticized for poor inter-observer reproducibility and for failing to capture the immunohistochemical and polymerase chain reaction analysis that modern pathology can provide. Contemporary biopsy interpretation includes immunohistochemical staining for T-cell and macrophage markers, and PCR for viral genomes (enterovirus, adenovirus, parvovirus B19, herpesvirus, CMV, SARS-CoV-2), which significantly improves diagnostic sensitivity over histology alone 5 / Solid .

Decisions Extended

Immunosuppression Decisions in Myocarditis

The TIMIC trial (2022) was a landmark positive trial: methylprednisolone 1 mg/kg/day tapering over 6 months significantly improved LVEF recovery at 6 months in patients with biopsy-proven viral genome-negative inflammatory myocarditis (change in EF +11.2 percent versus +3.0 percent in placebo; p<0.001) 5 / Solid 01354-6). The critical enrollment criterion was absence of viral genome on biopsy by PCR. In patients with active viral replication, immunosuppression during the viral phase could theoretically worsen myocardial injury by impairing viral clearance.

This distinction creates a practical clinical problem: most centers cannot obtain biopsy PCR results within the decision window in clinical practice. The TIMIC trial’s findings are theoretically applicable to genome-negative patients, but distinguishing genome-positive from genome-negative requires biopsy, which is not routinely performed for presumed viral myocarditis.

The current practical approach: immunosuppression is reserved for proven or highly suspected specific autoimmune myocarditis forms (GCM, cardiac sarcoidosis, eosinophilic myocarditis with identified trigger removed), and for patients with severe fulminant myocarditis with ongoing hemodynamic deterioration despite MCS support and treatment of any identified viral trigger. Empirical immunosuppression in all patients with myocarditis is not supported.

Mechanical Circulatory Support in Fulminant Myocarditis

Fulminant myocarditis (acute onset within 2 weeks of viral prodrome, rapid hemodynamic deterioration, severe biventricular dysfunction) has a paradoxical natural history: if the patient is supported through the acute phase, the probability of complete myocardial recovery is actually higher than in slower-onset non-fulminant myocarditis. The 11-year follow-up data from McCarthy et al. (1999) showed that patients with fulminant myocarditis who survived the acute phase with support had a transplant-free survival of 93 percent at 11 years, compared to only 45 percent for non-fulminant forms 4 / Promising .

This natural history finding strongly supports aggressive MCS deployment in fulminant myocarditis: the cardiologist who commits to Impella CP support, or VA-ECMO in refractory cases, and bridges the patient through 7 to 14 days of hemodynamic instability may achieve complete functional recovery. The cardiologist who does not deploy MCS because the prognosis seems grim is potentially abandoning a patient with a highly salvageable condition.

The specific MCS algorithm depends on which ventricle is predominantly failing:

• Isolated LV failure: intra-aortic balloon pump (IABP) as a first step, then Impella 2.5 or CP if IABP is insufficient
• Biventricular failure: VA-ECMO provides simultaneous biventricular support at the cost of higher complexity and LV distension (which may require additional LV venting with an Impella)
• The EURO-SHOCK trial and IMPRESS trials are relevant context for MCS in cardiogenic shock but included mixed etiologies, not myocarditis-specific data; myocarditis-specific MCS RCT data are lacking

The concept of “cardiac unloading and reverse remodeling” is particularly important in fulminant myocarditis: reducing LV end-diastolic volume and pressure with MCS may facilitate myocardial recovery by reducing wall stress and allowing the inflammatory process to resolve without ongoing mechanical overwork of the injured myocardium.

Return to Sport After Myocarditis

The 2020 ESC Cardiology in Sport Group consensus statement on return to sport after myocarditis recommends a minimum 3 to 6 month period of restriction from competitive athletics 5 / Solid . Return-to-play criteria require: normal LVEF on resting echocardiography, no complex ventricular arrhythmias on ambulatory monitoring, no pathological exercise-induced ventricular arrhythmia on treadmill testing, normalization of cardiac MRI inflammatory markers, and CRP normalization.

Athletes are at higher risk for sudden death in the context of active myocarditis because physical exertion increases catecholamine levels, which lower the ventricular fibrillation threshold in the presence of myocardial inflammation and heterogeneous repolarization. The restriction is not arbitrary; it is based on the mechanism of exercise-related sudden death in myocarditis patients.

High school and college athletes who develop myocarditis face significant emotional and practical consequences from activity restriction: loss of athletic season, potential scholarship implications, team disruption. Cardiologists managing these patients must be clear about the clinical rationale and provide a realistic timeline for return. A non-specific recommendation of “wait until you feel better” is not adequate when the athlete is asymptomatic but still has cardiac MRI evidence of ongoing inflammation.

Patient Evaluation Details

The Symptom Presentation Spectrum

Myocarditis presents across a remarkable clinical spectrum, from incidentally detected troponin elevation in an otherwise well patient to fulminant biventricular failure requiring mechanical support within 48 hours. Understanding this spectrum matters because the initial clinical presentation does not always predict the subsequent course.

Subclinical myocarditis: Troponin elevation detected incidentally or during workup for another condition. ECG may show non-specific T-wave changes. Echocardiography may show normal LV function. Cardiac MRI often shows focal late gadolinium enhancement. These patients are often found after viral infections or in the context of competitive athletics (where regular ECG screening identifies subtle findings). Management involves activity restriction, serial cardiac MRI, and close follow-up. Most resolve without sequelae.

Mild myocarditis: Chest pain (often sharp, pleuritic, resembling pericarditis) plus mild troponin elevation plus ECG changes plus mild or moderate LV dysfunction (LVEF 40 to 55 percent) on echocardiography. Patients are systemically well: no hemodynamic compromise, able to tolerate oral medications, ambulatory. These patients can often be managed with close inpatient monitoring for 24 to 48 hours, transitioning to outpatient management if stable.

Moderate myocarditis: Significant LV dysfunction (LVEF 25 to 40 percent), symptoms of heart failure (dyspnea, orthopnea, lower extremity edema), and raised BNP/NT-proBNP. Requires hospitalization, diuretics, ACE inhibitor, beta-blocker initiation when hemodynamically tolerated, and serial echocardiographic monitoring. These patients are not in immediate hemodynamic danger but require careful management because they can deteriorate.

Fulminant myocarditis: Acute onset within 2 weeks of viral prodrome, severe biventricular dysfunction (LVEF below 25 percent), hemodynamic instability requiring vasopressors, and often rapid progression to cardiogenic shock within hours. This is the category that requires MCS. Despite the severity, fulminant myocarditis paradoxically has better long-term outcomes than non-fulminant forms if the patient is supported through the acute phase.

Endomyocardial Biopsy Risk Stratification

Endomyocardial biopsy carries a real procedural risk that must be weighed against the diagnostic benefit. Published complication rates from experienced centers:

• Significant tricuspid regurgitation from bioptome trauma: 1 to 2 percent
• Ventricular perforation with hemopericardium: 0.3 to 0.5 percent
• Significant arrhythmia requiring treatment: 1 to 2 percent
• Death from procedure: less than 0.1 percent at high-volume centers

The risk increases substantially in patients with severe biventricular dysfunction: the dilated, thin-walled right ventricle is more vulnerable to perforation. In fulminant myocarditis with hemodynamic instability, the biopsy risk is highest precisely when the diagnostic yield (identifying giant cell myocarditis or eosinophilic myocarditis requiring specific immunosuppression) would be most valuable.

At high-volume myocarditis centers, the approach for fulminant presentations is often to proceed empirically with immunosuppression for suspected GCM/autoimmune myocarditis (high-dose methylprednisolone) while simultaneously deploying MCS, with biopsy deferred until the patient is hemodynamically stabilized. This balances the immediate therapeutic need against the procedural risk.

Evidence Extended

TIMIC Trial: Full Analysis and Implications

The TIMIC trial’s primary endpoint was a significant improvement in LVEF at 6 months (change in LVEF: +11.2 percent in the methylprednisolone group versus +3.0 percent in placebo; p<0.001). Secondary endpoints included hospitalization for HF, need for MCS, and time to clinical stabilization. All improved in the treatment arm.

The methylprednisolone protocol used in TIMIC: 1 mg/kg/day for 4 weeks, then tapering over the subsequent 20 weeks (1 mg/kg for 4 weeks, then 0.33 mg/kg for 4 weeks, then 0.165 mg/kg for 4 weeks, then 0.083 mg/kg for 4 weeks, then 0.041 mg/kg for 4 weeks, with final discontinuation at 24 weeks). This prolonged taper reduces the risk of rebound inflammation after corticosteroid withdrawal.

The TIMIC trial enrolled patients specifically on the basis of biopsy-proven viral genome-negative inflammatory myocarditis (confirmed by PCR for 7 viruses). This is a critical distinction: the trial does not apply to patients with active viral myocarditis where immunosuppression might be harmful, and it does not apply to patients without biopsy confirmation. In practice, applying TIMIC’s findings requires either biopsy (with PCR) to confirm genome-negative status, or a very high clinical confidence of autoimmune myocarditis based on other evidence (concurrent systemic autoimmune disease, cardiac MRI pattern, clinical course).

The BAMI trial (B-type natriuretic peptide-guided immunosuppression in myocarditis), a negative trial published in 2019, randomized myocarditis patients to guideline-based HF therapy versus immunosuppression with prednisolone and azathioprine, without requiring viral genome-negative biopsy as an inclusion criterion. BAMI showed no benefit of immunosuppression in this heterogeneous population 5 / Solid . The contrast with TIMIC’s positive result directly confirms that patient selection (genome-negative on biopsy) is the determinant of immunosuppression benefit.

Cardiac MRI Serial Follow-Up

For patients with myocarditis treated and recovering, serial cardiac MRI provides the most sensitive assessment of myocardial healing. The clinical MRI follow-up protocol at most academic centers:

• Acute presentation: CMR within 1 to 2 weeks of diagnosis (confirms myocarditis, establishes baseline LGE extent and location, quantifies edema)
• At 3 months: CMR to assess LVEF recovery and resolution of edema (T2 normalization is a favorable sign; persistent T2 elevation at 3 months suggests ongoing active inflammation)
• At 6 months: CMR for athletes who wish to return to sport (must show normal LVEF, no late gadolinium enhancement, normal T1/T2)
• At 12 months: CMR for patients with persistent LGE at 6 months (to determine whether fibrosis is stable or progressive)

The presence of LGE at 12 months after myocarditis is associated with higher long-term risk of arrhythmia and HF compared to patients with complete LGE resolution 4 / Promising . This informs the decision about implantable defibrillator placement.

Patient Experience Extended

The Young Athletic Patient

Myocarditis in young competitive athletes is a distinct clinical and emotional experience. The diagnosis interrupts a competitive career, potentially for months. For college athletes on scholarship, for professional athletes whose livelihood depends on performance, and for high school athletes whose identities are deeply linked to their sport, the activity restriction is not a minor inconvenience.

The cardiologist managing myocarditis in an athlete has two responsibilities in tension: protecting the patient from exercise-related sudden death during active inflammation (the restriction is medically necessary) and providing a clear, evidence-based timeline for return to activity that preserves the patient’s goals where possible.

The 2020 ESC Sports Cardiology consensus provides clear criteria (already detailed above). What the physician must communicate to the athlete, coach, and family:

1. Why the restriction is necessary: exercise during active myocardial inflammation dramatically increases the risk of ventricular fibrillation. This is not a theoretical concern; it is the most common cause of sudden death in young athletes in many series. The restriction is not optional.

2. What the monitoring plan consists of: specific tests (CMR, Holter, exercise stress test) at specific time points, with clear criteria that must be met before any return to sport.

3. What recovery looks like in most cases: the majority of young patients with uncomplicated myocarditis who complete appropriate monitoring and demonstrate full recovery return to prior athletic performance. The restriction is not necessarily a permanent end to athletic career.

4. When the news is less favorable: for patients with significant LGE on CMR that persists at 6 months, the risk-benefit calculation for return to competitive sports is genuinely uncertain. Some athletes in this category may be advised against return to competitive sport, with the understanding that recreational activity at lower intensity may be acceptable.

Myocarditis and Parenting: The Recovery Arc at Home

The majority of myocarditis patients are young to middle-aged adults with family and occupational obligations. The recovery period, which may involve activity restriction for 2 to 3 months, generates specific practical challenges: who drives the children to school when the patient cannot drive, how does the family manage on a reduced income if the patient is the primary earner, who manages the home while the patient is recovering.

These logistical dimensions of myocarditis recovery are rarely addressed in cardiology clinic encounters but are major determinants of whether the medical recommendations are followed. A patient who is told to rest and not exercise, but who has three children under the age of 8 and no childcare support, will not rest. The physician who provides the restriction without any acknowledgment of these practical realities is not practicing medicine in the patient’s actual life.

Social work consultation during myocarditis hospitalization (to assess family support, financial vulnerability, and logistical barriers to follow-up) is as much a part of the care plan as the CMR protocol.

Decisions Extended

The ICD Decision After Myocarditis

Implantable cardioverter-defibrillator (ICD) placement after myocarditis is among the most nuanced electrophysiology decisions in cardiology. The guidelines recommendations are not categorical:

ICD clearly indicated: Sustained VT or VF in the setting of myocarditis with LVEF below 35 percent that persists despite 3 months of guideline-directed medical therapy (GDMT). This follows standard primary prevention ICD criteria.

ICD decision is uncertain: Myocarditis with LVEF below 35 percent at 3 months, still recovering, with no documented sustained arrhythmia. Guidelines recommend completing 3 to 6 months of GDMT before deciding, because LVEF may recover significantly. Premature ICD implantation in patients whose LVEF recovers to above 35 percent results in an ICD that may not be needed.

ICD generally not indicated: Myocarditis with LVEF fully recovered to above 50 percent, no documented arrhythmia, and no high-risk LGE pattern.

For patients with myocarditis-related sustained arrhythmia whose LVEF is recovering but remains below 35 percent, a wearable defibrillator (LifeVest) bridges the period before a decision about permanent ICD can be made with confidence. LifeVest is worn continuously (except during showering) and delivers defibrillation therapy for VT/VF without requiring hospital admission. The data show LifeVest prevents arrhythmic death in selected patients with newly diagnosed cardiomyopathy during the period of LVEF monitoring 4 / Promising .

Heart Failure Management in Recovering Myocarditis

The management of LV dysfunction in myocarditis follows the same pharmacological architecture as other causes of heart failure with reduced ejection fraction (HFrEF), with one important caveat: in the acute inflammatory phase, some agents that are standard in HFrEF are not tolerated or may be contraindicated.

Beta-blockers: Have a negative inotropic effect that is beneficial in chronic HFrEF but can decompensate a patient in acute cardiogenic shock from fulminant myocarditis. Start low-dose when the patient is hemodynamically stable (systolic BP above 90, not on vasopressors, not in acute decompensation), then uptitrate slowly over weeks.

ACE inhibitors/ARBs: Generally well tolerated from an early stage; can be started once the patient is out of the acute shock period and creatinine is stable. Provide afterload reduction and prevent adverse LV remodeling.

Sacubitril-valsartan (Entresto): The PARADIGM-HF trial showed superiority of sacubitril-valsartan over enalapril for HFrEF outcomes 5 / Solid . For myocarditis patients whose LV dysfunction persists beyond 3 months, the transition from ACE inhibitor to sacubitril-valsartan follows the same criteria as in ischemic and non-ischemic cardiomyopathy.

SGLT2 inhibitors: Dapagliflozin and empagliflozin reduce hospitalization for heart failure and cardiovascular death in HFrEF patients regardless of diabetes status (DAPA-HF and EMPEROR-Reduced trials) 5 / Solid . These should be added to the regimen for myocarditis patients with persistent HFrEF at 3 months.

Diuretics: Used for symptomatic volume overload (pulmonary congestion, peripheral edema) without evidence-based mortality benefit. Dosing is guided by symptoms, weight, and BNP trajectory.

The full HFrEF regimen (ARNI + beta-blocker + MRA + SGLT2 inhibitor) is the current “fantastic four” of heart failure pharmacotherapy, applicable to myocarditis-related cardiomyopathy once acute recovery has reached a stable plateau.

Clinical Pearls and Institutional Resources

Myocarditis in Context: A Cardiologist’s Diagnostic Checklist

When a young patient presents with chest pain, raised troponin, and ECG changes that do not follow a coronary territory pattern, myocarditis belongs at the top of the differential. But arriving at the diagnosis requires ruling out the alternatives systematically:

Step 1: ECG interpretation. Myocarditis can show diffuse ST elevation (myopericarditis), focal ST changes mimicking ACS, new LBBB, prolonged QTc (often with right bundle branch block morphology), or non-specific T-wave changes. If ST elevation is focal and follows a coronary territory, ACS is more likely. If ST changes are diffuse and accompanied by PR depression, myopericarditis is more likely. If the ECG shows VT, rapid AF, or complete heart block, fulminant myocarditis must be considered.

Step 2: Echocardiography before catheterization. A regional wall motion abnormality on echo that corresponds to a specific coronary territory supports ACS as the cause of troponin elevation. Global LV dysfunction without regional pattern supports myocarditis or Takotsubo. A pericardial effusion supports myopericarditis. Normal LVEF with raised troponin and diffuse ECG changes supports myopericarditis with mild myocardial involvement.

Step 3: Decision about coronary angiography. For a 28-year-old with no CAD risk factors, viral prodrome, diffuse ECG changes, and global LV dysfunction, coronary angiography is still appropriate (to exclude coronary artery anomaly and SCAD as causes of the presentation), but it is not an emergency. For a 55-year-old with diabetes and hypertension presenting with new LBBB and depressed LVEF, ACS is the first diagnosis to exclude and angiography is urgent.

Step 4: Cardiac MRI timing. CMR is most sensitive for myocarditis when performed within 2 weeks of symptom onset, when the inflammatory edema is still present. After 4 to 6 weeks, T2 signal normalizes even if LGE persists. If CMR is planned for diagnosis, schedule it within the first 2 weeks; deferring to 6 weeks risks a false-negative result for active inflammation.

Geographic Access to Cardiac MRI

Cardiac MRI for myocarditis is not universally available. Not every hospital with an MRI scanner has the cardiac gating sequences, post-processing software, mapping sequences (T1 and T2), and radiologist or cardiologist expertise to interpret myocarditis-specific findings.

In Illinois: dedicated cardiac MRI programs exist at Northwestern Memorial Hospital (Chicago), University of Chicago Medicine, Rush University Medical Center, Loyola University Medical Center (Maywood), and Carle Foundation Hospital (Urbana). Each of these centers can perform CMR with late gadolinium enhancement, T1 and T2 mapping, and dedicated myocarditis protocols.

Patients presenting at community hospitals where CMR is not available may require transfer or outpatient referral to access this diagnostic tool. For a clinically stable patient with suspected myocarditis who does not require urgent CMR for an acute management decision, outpatient CMR scheduled within 7 to 10 days of diagnosis is appropriate. For a patient in fulminant myocarditis requiring immediate MCS decisions, CMR is not the priority tool. Bedside echocardiography, serial ECG monitoring, and hemodynamic assessment guide the acute phase management.

The Multi-Organ Autoimmune Framework

Cardiac sarcoidosis, a specific form of granulomatous myocarditis, deserves particular attention because it is under-recognized, treatable, and carries high arrhythmic risk if untreated. Sarcoidosis affects the heart in approximately 5 to 10 percent of patients with systemic sarcoidosis, but isolated cardiac sarcoidosis (no systemic involvement detected) accounts for an important subset.

The clinical presentations of cardiac sarcoidosis include:

• Unexplained complete heart block in patients under 55 (requires sarcoid workup)
• Sustained ventricular tachycardia in the absence of significant ischemic heart disease
• New-onset heart failure with patchy LGE on CMR not following a coronary territory
• Incidental CMR finding of mid-wall LGE with a pattern consistent with sarcoid (basal septal and lateral wall predilection)

The diagnostic workup for suspected cardiac sarcoidosis: CMR (characteristic LGE pattern; FDG-PET showing active granulomatous inflammation), whole-body FDG-PET (to detect extracardiac sarcoidosis that might provide a more accessible biopsy target than the heart), and endomyocardial biopsy if other sites are negative or unavailable.

The ICD decision in cardiac sarcoidosis is straightforward: sustained VT, LVEF below 35 percent despite steroid therapy, or complete heart block requiring pacing all represent ICD indications. The combination of ICD and cardiac resynchronization (CRT-D) is appropriate in patients with significant conduction system disease and reduced LVEF 5 / Solid .

Steroid therapy for cardiac sarcoidosis: prednisone 40 to 60 mg/day initially, tapered over 12 months. The goal is to suppress active granulomatous inflammation (as measured by FDG-PET and CMR) while managing steroid side effects. Not all patients respond; some develop steroid-resistant disease requiring second-line agents (methotrexate, azathioprine, mycophenolate).

The Athlete Returning to Sport: Case-Based Decision Framework

A 22-year-old competitive cyclist presents with chest pain and dyspnea 10 days after a flu-like illness. Troponin is raised. ECG shows diffuse T-wave inversions in V2-V6. Echo shows LVEF of 48 percent. CMR shows subepicardial LGE in the inferolateral wall, T2 elevation in the same territory, no pericardial effusion.

Diagnosis: myocarditis (viral/inflammatory), confirmed by CMR.

Management: activity restriction (no aerobic training, no competition), anti-inflammatory therapy for concurrent pericarditis component if CRP is raised and pericardial involvement is noted, beta-blocker if LVEF remains below 50 percent at 2 weeks, serial cardiac monitoring.

Return-to-sport evaluation at 3 months: LVEF fully recovered to 56 percent. CMR shows no edema (T2 normal), persistent mild subepicardial LGE in inferolateral wall (small focus). 24-hour Holter: no complex ventricular arrhythmia, no more than 50 isolated PVCs in 24 hours. Symptom-limited exercise treadmill test: no exercise-induced arrhythmia, normal BP response, 12 METS achieved.

Decision: meet all ESC criteria for return to sport with monitoring. Counsel that the small residual LGE represents healed scar but is not an absolute contraindication to competitive sport at the current evidence level. Recommend annual CMR to confirm LGE stability. Return to cycling training with gradual reintroduction over 4 to 6 weeks.

This case represents the typical trajectory for a young athlete with uncomplicated myocarditis. The 3-month activity restriction, the CMR-confirmed recovery, and the structured return-to-sport protocol are the components of a complete clinical response.

Diagnostic Challenges and the Biopsy Decision

10.1 When to Biopsy: The Clinical Algorithm

Endomyocardial biopsy (EMB) is not a routine step in most myocarditis workups. It is invasive, it has a sampling error problem (inflammation is patchy and a standard bioptome sample three to five small cores from the RV septum, which may miss focal disease), and it requires a center with pathological expertise in immunohistochemistry and electron microscopy. The clinical question is: when does the answer the biopsy provides change management enough to justify the procedural risk?

The American Heart Association/ACC/ESC consensus recommends EMB in the following scenarios 5 / Solid :

1. Unexplained new-onset HF of fewer than two weeks duration with a normal-sized or dilated LV and hemodynamic compromise. This is the scenario most likely to represent giant cell myocarditis (GCM), which responds to immunosuppression and which is uniformly fatal without a cardiac transplant in most cases.
2. Unexplained new-onset HF of two weeks to three months duration with a dilated LV, new ventricular arrhythmias or Mobitz II or third-degree AV block, or failure to respond to usual care within one to two weeks.
3. Unexplained HF greater than three months with a dilated LV, new ventricular arrhythmias or Mobitz II or third-degree AV block, or failure to respond to usual care.

Outside these scenarios, CMR has largely supplanted EMB for diagnosis confirmation in uncomplicated myocarditis. The Lake Louise Criteria on CMR (T2-based edema, T1-based tissue characterization, and late gadolinium enhancement) have a sensitivity of 88 percent and specificity of 96 percent for myocarditis in experienced hands 5 / Solid .

10.2 Giant Cell Myocarditis: The Biopsy That Cannot Wait

Giant cell myocarditis (GCM) is a distinct histological entity from lymphocytic myocarditis. It is rare, with an estimated incidence of 0.3 cases per million population per year 3 / Early . It is rapidly fatal: median survival without heart transplantation is five months from symptom onset 5 / Solid . The histological finding is multinucleated giant cells in the myocardium with extensive necrosis. The clinical presentation is rapid deterioration: patients with GCM are frequently in the ICU within days of symptom onset, with complete heart block, ventricular tachycardia, and progressive cardiogenic shock.

The only intervention that changes the natural history of GCM is heart transplantation. The bridge to transplantation requires: aggressive immunosuppression with high-dose corticosteroids plus azathioprine or cyclosporine (shown to extend survival in the GCM Treatment Trial, Promising; Cooper LT et al., 1997), mechanical circulatory support with Impella or ECMO, and listing for cardiac transplantation with the highest urgency (United Network for Organ Sharing Status 1 listing in the United States).

The reason this matters for every cardiologist managing severe myocarditis: biopsy must happen urgently when GCM is suspected. The specific clinical triggers for immediate biopsy are: complete heart block without an identifiable structural cause; ventricular tachycardia in the context of acute myocarditis; failure to improve on standard supportive care within 24 to 48 hours. In Illinois, Carle Foundation Hospital collaborates with Northwestern Memorial Hospital’s advanced heart failure and transplant program in Chicago for GCM cases requiring biopsy and urgent transplant listing.

10.3 Return-to-Sport: The Decision Algorithm for Athletes

The 2020 ACC/AHA Scientific Statement on cardiology care in competitive athletes recommends a minimum three to six month period of withdrawal from competitive sport after myocarditis diagnosis 5 / Solid . Return-to-sport criteria include:

• Normalization of EF (above 50 percent) on repeat echocardiography.
• Absence of ventricular arrhythmias on a 24-hour Holter monitor or exercise stress test.
• Resolution of CMR findings: no active edema on T2; no progressive late gadolinium enhancement.
• Normalization of serum troponin.

The decision is not binary. A 22-year-old college soccer player with recovered EF, no arrhythmias, and complete CMR resolution can return to competitive sport at six months with shared decision-making. A 28-year-old recreational runner with persistent late gadolinium enhancement at six months is advised to avoid competitive sport for a minimum of one year and potentially indefinitely, depending on the distribution and extent of LGE.

The conversation about LGE and long-term risk is one the athlete patient deserves to hear directly. Persistent LGE at 12 months is present in 20 to 40 percent of myocarditis survivors 4 / Promising . Its significance as a predictor of long-term arrhythmic risk is not yet established in large prospective trials. What is established: LGE represents fibrosis, and myocardial fibrosis is an arrhythmogenic substrate. The patient should not be told “everything is fine” when LGE persists. She should be told: “This finding requires annual cardiac MRI surveillance and discussion of activity limitations each year as we gather more data.”

10.4 COVID-19 Vaccine-Associated Myocarditis: What the Evidence Shows

Myocarditis following mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) was first reported in May 2021. The signal is concentrated in males aged 12 to 29, with the highest incidence after the second dose of Moderna 5 / Solid . The incidence per million doses in the highest-risk group is 105.9 per million in males 16 to 17 after dose 2 of Pfizer, and higher for Moderna in males 18 to 24.

The clinical course of vaccine-associated myocarditis is almost uniformly mild and self-limited. Hospitalization is brief (median 2 to 4 days), cardiac MRI findings are typically minimal, EF recovery is nearly universal, and arrhythmia is rare 5 / Solid . The contrast with COVID-19-associated myocarditis is stark: myocarditis from active COVID-19 infection is more severe, more likely to require ICU care, and more likely to produce persistent LV dysfunction.

This context is essential for patient communication. A young man who develops chest pain three days after his second COVID-19 vaccine, is admitted with raised troponin and ECG changes, and is told he has “vaccine-associated myocarditis” deserves a complete clinical explanation: the natural history is favorable; the risk of not being vaccinated (including COVID-19-related myocarditis and other complications) exceeds the risk of vaccine-associated myocarditis in almost all scenarios; and the follow-up protocol is the same as for any myocarditis case.

Dr. Job Mogire, MD FACP FACC. Carle Foundation Hospital; Carle Illinois College of Medicine. Stop Dying Early.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.